The present disclosure relates to antibodies or fragments thereof that target at least one conformational epitope of a Notch 3 or mutant Notch 3 receptor; and compositions and methods of use thereof.

The present invention related to a method for detecting a history of exposure to a chemical(s) comprising measuring the concentration of thrombomodulin in a sample isolated from a subject, and determining whether the concentration of thrombomodulin is altered compared to control reference levels.

In various embodiments, the application relates to methods for assessment of cardiovascular disease (CVD) risk in a patient comprising comparing pre-heparin LPL (lipoprotein lipase) levels which are associated with protection from CVD to remnant lipoprotein cholesterol (RLP-C) and/or remnant lipoprotein triglyceride content (RLP-Tg).

The invention provides methods for identifying a patient as likely to have an onset of massive hemorrhage. In one embodiment, the invention provides a method for identifying a patient as likely to have an onset of massive hemorrhage, the method comprising measuring at least one of first coagulation characteristic parameter reflective of a clotting time in a sample of blood of the patient, a second coagulation characteristic parameter reflective of clot formation in a sample of blood of the patient using the viscoelastic assay to obtain a second result; a third coagulation characteristic parameter reflective of clot strength in a sample of blood of the patient using the viscoelastic assay to obtain a third result; and a fourth coagulation characteristic parameter reflective of clot lysis in a sample of blood of the patient using the viscoelastic assay to obtain a fourth result; wherein, a positive for at least one of the first result, second result, third result and fourth result identifies the patient as likely to have an onset of massive hemorrhage.

The invention provides novel compositions and methods for the treatment of Radiation-Induced Bystander Effects (RIBE), resulting from radiation exposure. In one preferred embodiment the inventions includes novel therapeutic agents, including but not limited to quercetin and quercetin analogs, as well as E64, CA074, CA074Me, that interfere with the activity of Cathepsin B.

The present invention relates to the filed of diagnostic and/or prognostic and/or subject stratification biomarker assays for the prognosis and/or diagnosis and/or therapy of high risk early psychosis subjects, wherein psychotic disorder may include schizophrenia, bipolar disorder (manic depression), epilepsy, mood disorder, age-related disorders, or cognitive impairment, or another psychotic disorder. The expression markers used are miR-137 and COX6A2. The present invention also relates to the use of mitochondria-targeted antioxidant in the treatment of subjects classified as high-risk early psychosis subjects and to a kit comprising means for determining said markers.

A method of predicting a sepsis condition in a subject, comprising: a. determining a level of a biomarker in a sample of said subject, wherein the biomarker is of structure (I): Formula (I) or a salt thereof; and b. comparing said level to a predetermined reference value of the biomarker, wherein an elevated biomarker level is indicative of the risk of the sepsis condition.

##STR00001##

The present invention includes a method for determining pre-term birth or an associated clinical condition or an increased risk of pre-term birth or an associated clinical condition based on the presence and/or increased amount of specific amnion and/or chorion cells in a blood sample from a pregnant woman.

Compositions and methods are presented that allow for detection and prediction of an immune response in a subject that is selected to receive or that has received a vaccine. In selected embodiments, whole blood is used as starting material to obtain both dendritic cells and T cells, and synthetic or recombinant polypeptide(s) are used that include an antigen of the vaccine. The dendritic cells are then exposed to the synthetic or recombinant polypeptide(s), and thusly exposed dendritic cells are combined with the T cells to generate antigen reactive T cells. For detection or quantification, the antigen reactive T cells are expanded in vitro prior to ELISPOT or FACS analysis. Advantageously, such systems and methods are especially suitable for ascertaining an immune response against cancer antigens following vaccination with an anti-cancer vaccine.

The present invention provides ST6GAL1, GALNT7, FUT8 and GCNT1 as novel biological fluid (e.g. blood or urine) biomarkers for prostate cancer. Methods for diagnosing prostate cancer or the risk of developing prostate cancer, or for monitoring prostate cancer progression (including prostate cancer relapse) and methods for treatment of prostate cancer are also provided. The invention also provides methods for determining the therapeutic effect of appropriate treatment regimens for prostate cancer or determining a subject's compliance or adherence with a prescribed treatment regimen for prostate cancer. Corresponding kits, assay devices and uses are also provided.